NeuroSense Therapeutics (NRSN) Invested Capital (2021 - 2023)

NeuroSense Therapeutics has reported Invested Capital for 3 years, with the latest figure at $73000.0 in Q4 2023.

• Quarterly Invested Capital fell 50.34% year-over-year to $73000.0 in Q4 2023, while the trailing twelve-month figure through Sep 2024 was $73000.0 (down 50.34% YoY) and the FY2023 annual result came in at $73000.0, down 50.34% from the prior year.
• Invested Capital declined to $73000.0 in Q4 2023 per NRSN's latest filing, from $147000.0 in the prior quarter.
• Over five years, Invested Capital peaked at $1.8 million in Q4 2021 and troughed at $73000.0 in Q4 2023.
• A 3-year average of $579000.0 and a median of $207500.0 in 2022 frame the typical range for Invested Capital.
• The sharpest annual moves came in 2022 and 2023: Invested Capital tumbled 91.96% in 2022, then plunged 50.34% in 2023.
• Over 3 years, Invested Capital stood at $1.8 million in 2021, then sank by 91.96% to $147000.0 in 2022, then slumped by 50.34% to $73000.0 in 2023.
• According to Business Quant data, Invested Capital over the past three periods registered $73000.0, $147000.0, and $268000.0 for Q4 2023, Q4 2022, and Q2 2022 respectively.